DOCSLIB.ORG

ATC Vet 2015 Atccode Atcdescription Atcdescriptionsi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ATC Vet 2015 ATCCode ATCDescription ATCDescriptionSI QA ALIMENTARY TRACT AND METABOLISM ZDRAVILA ZA BOLEZNI PREBAVIL IN PRESNOVE QA01 STOMATOLOGICAL PREPARATIONS ZDRAVILA V ZOBOZDRAVSTVU QA01A Stomatological preparations Zdravila v zobozdravstvu QA01AA Caries prophylactic agents Zdravila za zaščito pred zobnim kariesom QA01AA01 sodium fluoride natrijev fluorid QA01AA02 sodium monofluorophosphate natrijev monofluorofosfat QA01AA03 olaflur olaflur QA01AA04 stannous fluoride kositrov(II) fluorid QA01AA30 combinations kombinacije QA01AA51 sodium fluoride, combinations natrijev fluorid, kombinacije QA01AB Antiinfectives and antiseptics for local oral treatment Protimikrobne učinkovine in antiseptiki za lokalno oralno zdravljenje QA01AB02 hydrogen peroxide vodikov peroksid QA01AB03 chlorhexidine klorheksidin QA01AB04 amphotericin B amfotericin B QA01AB05 polynoxylin polinoksilin QA01AB06 domiphen domifen QA01AB07 oxyquinoline oksikinolin QA01AB08 neomycin neomicin QA01AB09 miconazole mikonazol QA01AB10 natamycin natamicin QA01AB11 various razne učinkovine QA01AB12 hexetidine heksetidin QA01AB13 tetracycline tetraciklin QA01AB14 benzoxonium chloride benzoksonijev klorid QA01AB15 tibezonium iodide tibezonijev jodid QA01AB16 mepartricin mepartricin QA01AB17 metronidazole metronidazol QA01AB18 clotrimazole klotrimazol QA01AB19 sodium perborate natrijev perborat QA01AB20 antiinfectives for local oral treatment, combinations protimikrobne učinkovine za lokalno oralno zdravljenje, kombinacije QA01AB21 chlortetracycline klortetraciklin QA01AB22 doxycycline doksiciklin QA01AB23 minocycline minociklin QA01AC Corticosteroids for local oral treatment Kortikosteroidi za lokalno oralno zdravljenje QA01AC01 triamcinolone triamcinolon QA01AC02 dexamethasone deksametazon QA01AC03 hydrocortisone hidrokortizon QA01AC54 prednisolone, combinations prednizolon, kombinacije QA01AD Other agents for local oral treatment Druga zdravila za lokalno oralno zdravljenje QA01AD01 epinephrine adrenalin QA01AD02 benzydamine benzidamin QA01AD05 acetylsalicylic acid acetilsalicilna kislina QA01AD06 adrenalone adrenalon QA01AD07 amlexanox amleksanoks QA01AD08 becaplermin bekaplermin QA01AD11 various razne učinkovine QA02 DRUGS FOR ACID RELATED DISORDERS ZDRAVILA ZA KISLINSKO POGOJENE BOLEZNI QA02A Antacids Antacidi QA02AA Magnesium compounds Magnezijeve spojine QA02AA01 magnesium carbonate magnezijev karbonat QA02AA02 magnesium oxide magnezijev oksid QA02AA03 magnesium peroxide magnezijev peroksid QA02AA04 magnesium hydroxide magnezijev hidroksid QA02AA05 magnesium silicate magnezijev silikat QA02AA10 combinations kombinacije QA02AB Aluminium compounds Aluminijeve spojine QA02AB01 aluminium hydroxide aluminijev hidroksid QA02AB02 algeldrate algeldrat QA02AB03 aluminium phosphate aluminijev fosfat QA02AB04 dihydroxialumini sodium carbonate dihidroksialuminijev natrijev karbonat QA02AB05 aluminium acetoacetate aluminijev acetoacetat QA02AB06 aloglutamol aloglutamol Stran 1 od 115 ATC Vet 2015 ATCCode ATCDescription ATCDescriptionSI QA02AB07 aluminium glycinate aluminijev glicinat QA02AB10 combinations kombinacije QA02AC Calcium compounds Kalcijeve spojine QA02AC01 calcium carbonate kalcijev karbonat QA02AC02 calcium silicate kalcijev silikat QA02AC10 combinations kombinacije QA02AD Combinations and complexes of aluminium, calcium and magnesium compounds Zdravila z aluminijem, kalcijem in magnezijem QA02AD01 ordinary salt combinations običajne kombinacije soli QA02AD02 magaldrate magaldrat QA02AD03 almagate almagat QA02AD04 hydrotalcite hidrotalcit QA02AD05 almasilate almasilat QA02AF Antacids with antiflatulents Antacidi s karminativi QA02AF01 magaldrate and antiflatulents magaldrat in karminativi QA02AF02 ordinary salt combinations and antiflatulents običajne kombinacije soli in antiflatulenti QA02AG Antacids with antispasmodics Antacidi s spazmolitiki QA02AH Antacids with sodium bicarbonate Antacidi z natrijevim hidrogenkarbonatom QA02AX Antacids, other combinations Antacidi, druge kombinacije QA02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Zdravila za zdravljenje peptične razjede in gastroezofagealne refluksne bolezni (GERB) QA02BA H2-receptor antagonists Antagonisti histaminskih receptorjev H2 QA02BA01 cimetidine cimetidin QA02BA02 ranitidine ranitidin QA02BA03 famotidine famotidin QA02BA04 nizatidine nizatidin QA02BA05 niperotidine niperotidin QA02BA06 roxatidine roksatidin QA02BA07 ranitidine bismuth citrate ranitidin-bizmutov citrat (kompleks ranitidina in bizmutovega citrata) QA02BA08 lafutidine lafutidin QA02BA51 cimetidine, combinations cimetidin, kombinacije QA02BA53 famotidine, combinations famotidin, kombinacije QA02BB Prostaglandins Prostaglandini QA02BB01 misoprostol mizoprostol QA02BB02 enprostil enprostil QA02BC Proton pump inhibitors Zaviralci protonske črpalke QA02BC01 omeprazole omeprazol QA02BC02 pantoprazole pantoprazol QA02BC03 lansoprazole lansoprazol QA02BC04 rabeprazole rabeprazol QA02BC05 esomeprazole esomeprazol QA02BC06 dexlansoprazole dekslansoprazol QA02BD Combinations for eradication of Helicobacter pylori Kombinacije učinkovin za zdravljenje okužb z bakterijo Helicobacter pylori QA02BD01 omeprazole, amoxicillin and metronidazole omeprazol, amoksicilin in metronidazol QA02BD02 lansoprazole, tetracycline and metronidazol lansoprazol, tetraciklin in metronidazol QA02BD03 lansoprazole, amoxicillin and metronidazol lansoprazol, amoksicilin in metronidazol QA02BD04 pantoprazole, amoxicillin and clarithromycin pantoprazol, amoksicilin in klaritromicin QA02BD05 omeprazole, amoxicillin and clarithromycin omeprazol, amoksicilin in klaritromicin QA02BD06 esomeprazole, amoxicillin and clarithromycin esomeprazol, amoksicilin in klaritromicin QA02BD07 lansoprazole, amoxicillin and clarithromycin lansoprazol, amoksicilin in klaritromicin QA02BD08 bismuth subcitrate, tetracycline and metronidazole bizmutov subcitrat, tetraciklin in metronidazol QA02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Druga zdravila za zdravljenje peptične razjede in gastroezofagealne refluksne bolezni (GERB) QA02BX01 carbenoxolone karbenoksolon QA02BX02 sucralfate sukralfat (aluminijev saharozni sulfat) QA02BX03 pirenzepine pirenzepin QA02BX04 methiosulfonium chloride metiosulfonijev klorid QA02BX05 bismuth subcitrate bazični bizmutov citrat QA02BX06 proglumide proglumid QA02BX07 gefarnate gefarnat QA02BX08 sulglicotide sulglikotid QA02BX09 acetoxolone acetoksolon QA02BX10 zolimidine zolimidin QA02BX11 troxipide troksipid QA02BX12 bismuth subnitrate bazični bizmutov nitrat Stran 2 od 115 ATC Vet 2015 ATCCode ATCDescription ATCDescriptionSI QA02BX13 alginic acid alginska kislina QA02BX51 carbenoxolone, combinations excl. psycholeptics karbenoksolon, kombinacije brez psiholeptikov QA02BX71 carbenoxolone, combinations with psycholeptics karbenoksolon, kombinacije s psiholeptiki QA02BX77 gefarnate, combinations with psycholeptics gefarnat, kombinacije s psiholeptiki QA02X Other drugs for acid related disorders Druga zdravila za kislinsko pogojene bolezni QA03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ZDRAVILA ZA ZDRAVLJENJE GASTROINTESTINALNIH FUNKCIONALNIH MOTENJ QA03A Drugs for functional gastrointestinal disorders Zdravila za zdravljenje gastrointestinalnih funkcionalnih motenj QA03AA Synthetic anticholinergics, esters with tertiary amino group Sintezni antiholinergiki, estri s terciarno aminoskupino QA03AA01 oxyphencyclimine oksifenciklimin QA03AA03 camylofin kamilofin QA03AA04 mebeverine mebeverin QA03AA05 trimebutine trimebutin QA03AA06 rociverine rociverin QA03AA07 dicycloverine dicikloverin QA03AA08 dihexyverine diheksiverin QA03AA09 difemerine difemerin QA03AA30 piperidolate piperidolat QA03AB Synthetic anticholinergics, quaternary ammonium compounds Sintezni antiholinergiki s kvaterno amonijevo skupino QA03AB01 benzilone benzilon QA03AB02 glycopyrronium glikopironium QA03AB03 oxyphenonium oksifenonium QA03AB04 penthienate pentienat QA03AB05 propantheline propantelin QA03AB06 otilonium bromide otilonijev bromid QA03AB07 methantheline metantelin QA03AB08 tridihexethyl tridiheksetil QA03AB09 isopropamide izopropamid QA03AB10 hexocyclium heksociklium QA03AB11 poldine poldin QA03AB12 mepenzolate mepenzolat QA03AB13 bevonium bevonium QA03AB14 pipenzolate pipenzolat QA03AB15 diphemanil difemanil QA03AB16 (2-benzhydryloxyethyl)diethyl-methylammonium iodide (2-benzhidriloksietil)dietilmetilamonijev jodid QA03AB17 tiemonium iodide tiemonijev jodid QA03AB18 prifinium bromide prifinijev bromid QA03AB19 timepidium bromide timepedijev bromid QA03AB21 fenpiverinium fenpiverinium QA03AB53 oxyphenonium, combinations oksifenonium, kombinacije QA03AB90 benzetimide benzetimid QA03AB92 carbachol karbahol QA03AB93 neostigmin neostigmin QA03AC Synthetic antispasmodics, amides with tertiary amines Sintezni spazmolitiki, amidi s terciarno aminoskupino QA03AC02 dimethylaminopropionylphenothiazine dimetilaminopropionilfenotiazin QA03AC04 nicofetamide nikofetamid QA03AC05 tiropramide tiropramid QA03AD Papaverine and derivatives Papaverin in njegovi derivati QA03AD01 papaverine papaverin QA03AD02 drotaverine drotaverin QA03AD30 moxaverine moksaverin QA03AE Serotonin receptor antagonists Antagonisti serotoninskih receptorjev QA03AE01 alosetron alosetron QA03AE03 cilansetron cilansetron QA03AX Other drugs for functional gastrointestinal disorders Druga zdravila za zdravljenje gastrointestinalnih funkcionalnih motenj QA03AX01 fenpiprane fenpipran QA03AX02 diisopromine diizopromin QA03AX03 chlorbenzoxamine klorbenzoksamin QA03AX04 pinaverium
Recommended publications
  • Full Text in Pdf Format

    Full Text in Pdf Format

    DISEASES OF AQUATIC ORGANISMS Published July 30 Dis Aquat Org Oral pharmacological treatments for parasitic diseases of rainbow trout Oncorhynchus mykiss. 11: Gyrodactylus sp. J. L. Tojo*, M. T. Santamarina Department of Microbiology and Parasitology, Laboratory of Parasitology, Faculty of Pharmacy, Universidad de Santiago de Compostela, E-15706 Santiago de Compostela, Spain ABSTRACT: A total of 24 drugs were evaluated as regards their efficacy for oral treatment of gyro- dactylosis in rainbow trout Oncorhj~nchusmykiss. In preliminary trials, all drugs were supplied to infected fish at 40 g per kg of feed for 10 d. Twenty-two of the drugs tested (aminosidine, amprolium, benznidazole, b~thionol,chloroquine, diethylcarbamazine, flubendazole, levamisole, mebendazole, n~etronidazole,mclosamide, nitroxynil, oxibendazole, parbendazole, piperazine, praziquantel, roni- dazole, secnidazole, tetramisole, thiophanate, toltrazuril and trichlorfon) were ineffective Triclabenda- zole and nitroscanate completely eliminated the infection. Triclabendazole was effective only at the screening dosage (40 g per kg of feed for 10 d), while nitroscanate was effective at dosages as low as 0.6 g per kg of feed for 1 d. KEY WORDS: Gyrodactylosis . Rainbow trout Treatment. Drugs INTRODUCTION to the hooks of the opisthohaptor or to ulceration as a result of feeding by the parasite. The latter is the most The monogenean genus Gyrodactylus is widespread, serious. though some individual species have a restricted distri- Transmission takes place largely as a result of direct bution. Gyrodactyloses affect numerous freshwater contact between live fishes, though other pathways species including salmonids, cyprinids and ornamen- (contact between a live fish and a dead fish, or with tal fishes, as well as marine fishes including gadids, free-living parasites present in the substrate, or with pleuronectids and gobiids.
  • Benznidazole(Rinn)

    Benznidazole(Rinn)

    830 Antiprotozoals Uses and Administration in endemic areas. It may also be used for prophylaxis in non- Neth.: Wellvone; Port.: Wellvone; S.Afr.: Wellvone; Spain: Wellvone; Atovaquone is a hydroxynaphthoquinone antiprotozo- immune travellers9,10 and appears to be well tolerated.10,11 Swed.: Wellvone; Switz.: Wellvone; UK: Wellvone; USA: Mepron. 1. Chiodini PL, et al. Evaluation of atovaquone in the treatment of Multi-ingredient: Austral.: Malarone; Austria: Malarone; Promal; Belg.: al that is also active against the fungus Pneumocystis patients with uncomplicated Plasmodium falciparum malaria. J Malarone; Canad.: Malarone; Cz.: Malarone; Denm.: Malarone; Fr.: Ma- jirovecii. It is used in the treatment and prophylaxis of Antimicrob Chemother 1995; 36; 1073–5. larone; Ger.: Malarone; Gr.: Malarone; Hong Kong: Malarone; Hung.: Ma- larone; Irl.: Malarone; Israel: Malarone; Ital.: Malarone; Malaysia: Malar- pneumocystis pneumonia in patients unable to tolerate 2. Looareesuwan S, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of one; Neth.: Malarone; Norw.: Malarone; NZ: Malarone; Pol.: Malarone; co-trimoxazole, and with proguanil in the treatment acute uncomplicated malaria in Thailand. Am J Trop Med Hyg S.Afr.: Malanil; Singapore: Malarone; Spain: Malarone; Swed.: Malarone; Switz.: Malarone; UK: Malarone; USA: Malarone. and prophylaxis of malaria. 1996; 54: 62–6. 3. Radloff PD, et al. Atovaquone and proguanil for Plasmodium In the treatment of mild to moderate pneumocystis falciparum malaria. Lancet 1996; 347: 1511–14. pneumonia, atovaquone is given orally in a dose of 4. Sabchareon A, et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Azanidazole (BAN, USAN, rINN) 750 mg with food twice daily as a suspension, for 21 Plasmodium falciparum malaria.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • (12) Patent Application Publication (10) Pub. No.: US 2001/0053775 A1 Seidel Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2001/0053775 A1 Seidel Et Al

    US 2001.0053775A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2001/0053775 A1 Seidel et al. 43) Pub. Date: Dec. 20,9 2001 (54) NASAL SOLUTIONS (30) Foreign Application Priority Data (76) Inventors: Matthias Seidel, Ittigen (CH); Jan. 30, 1998 (EP)........................................ 9881OO69-9 Christopher Buckley, Commugny (CH) Publication Classification Correspondence Address: RVNSporation (51) Int. Cl." ......................... A61K 31156; A61K 31/57; ENNINEMARK DEPT (52) U.S. Cl. ........................"I,...s. SUMMIT, NJ 079011027 (21) Appl. No.: 09/880,678 (57) ABSTRACT (22) Filed: Jun. 13, 2001 Related U.S. Application Data The invention relates to liquid pharmaceutical compositions adapted to nasal administration. The liquid nasal formula (63) Continuation of application No. 09/601,123, filed on tions of the invention are characterized inter alia by having Jul. 27, 2000. excellent and prolonged moisturizing properties. US 2001/0053775 A1 Dec. 20, 2001 NASAL SOLUTIONS embodiment of the invention they may also be present in a 0001. The present invention relates to pharmaceutical Slightly Viscous form, e.g. like a Syrup. However, they all compositions intended for nasal administration. More Spe can be clearly discriminated from nasal formulations in gel cifically, it concerns liquid nasal formulations with form in that they-in contrast to gels-are able to form improved moisturizing properties. drops and can be used as SprayS. 0014) Active substances suitable for nasal administration 0002 The nasal administration of active substances is a (a) are e.g. vasoconstrictors, e.g. Xylometazoline, e.g. widely used method of treatment. Active substances which Xylometazoline hydrochloride; indanazoline, metizoline; come into consideration are, for example, vasoconstrictors, naphazoline, e.g.
  • Epinephrine Versus Tramazoline to Reduce Nasal Bleeding During Nasotracheal Intubation. a Double- Blind Randomized Trial

    Epinephrine Versus Tramazoline to Reduce Nasal Bleeding During Nasotracheal Intubation. a Double- Blind Randomized Trial

    Epinephrine versus tramazoline to reduce nasal bleeding during nasotracheal intubation. A double- blind randomized trial Aiji Sato(Boku) ( [email protected] ) Aichi Gakuin University Yoshiki Sento Nagoya City University Yuji Kamimura Nagoya City University Eisuke Kako Nagoya City University Masahiro Okuda Aichi Gakuin University Naoko Tachi Aichi Gakuin University Yoko Okumura Aichi Gakuin University Mayumi Hashimoto Aichi Gakuin University Hiroshi Hoshijima Tohoku University Fumihito Suzuki Akita National Hospital Kazuya Sobue Nagoya City University Research Article Keywords: Nasotracheal intubation, Epinephrine, Tramazoline, Nasal bleeding Posted Date: February 10th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-148779/v1 Page 1/14 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/14 Abstract BACKGROUND Nasal bleeding is the most common complication during nasotracheal intubation (NTI). To reduce nasal bleeding, the nasal cavity is treated with vasoconstrictors (epinephrine [E] or tramazoline [T]) prior to NTI. This study aimed to determine whether E or T is more effective and safe for reducing nasal bleeding during NTI. METHODS This study was preregistered on UMIN-CTR after being approved by the IRB of the School of Dentistry at Aichi Gakuin University. Written consent was received from all the patients. Total 206 patients aged 20–70 years and classied as 1–2 on American Society of Anesthesiologists-physical status were scheduled to undergo general anesthesia with NTI. Patients with a narrowed nasal cavity observed during preoperative CT test (n = 3), patients with hypertension (n = 3), patients undergoing antithrombotic therapy, and patients who did not give consent (n = 3) were excluded from the study.
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
  • Wo 2010/075090 A2

    Wo 2010/075090 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS

    Pharmacology on Your Palms CLASSIFICATION of the DRUGS

    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
  • Workbook Psychiatry and Narcology

    Workbook Psychiatry and Narcology

    Kharkiv National Medical University Department of Psychiatry, Narcology and Medical Psychology WORKBOOK MANUAL FOR INDIVIDUAL WORK FOR MEDICAL STUDENTS PSYCHIATRY AND NARCOLOGY (Part 2) Student ___________________________________________________________ Faculty _________________________________________________________ Course _________________ Group _____________________________________ Kharkiv 2019 Затверджено вченою радою ХНМУ Протокол №5 від 23.05.2019 р. Psychiatry (Part 2) : workbook manual for individual work of students / I. Strelnikova, G. Samardacova, К. Zelenska – Kharkiv, 2019. – 103 p. Копіювання для розповсюдження в будь-якому вигляді частин або повністю можливо тільки з дозволу авторів навчального посібника. CLASS 7. NEUROTIC DISORDERS. CLINICAL FORMS. TREATMENT AND REHABILITATION. POSTTRAUMATIC STRESS DISORDER. TREATMENT AND REHABILITATION. Psychogenic diseases are a large and clinically varied group of diseases resulting from an effect of acute or long-term psychic traumas, which manifest themselves by both mental and somatoneurological disorders and, as a rule, are reversible. Psychogenic diseases are caused by a psychic trauma, i.e. some events which affect significant aspects of existence of the human being and result in deep psychological feelings. These may be subjectively significant events, i.e. those which are pathogenic for the majority of people. Besides, the psyche may be traumatized by conventionally pathogenic events, which cause feelings in an individual because of his peculiar hierarchy of values. Unfavorable psychogenic effects on the human being cause stress in him, i.e. a nonspecific reaction at the physiological, psychological and behavioural levels. Stress may exert some positive, mobilizing influence, but may result in disorganization of the organism activity. The stress, which exerts a negative influence and causes various disturbances and even diseases, is termed distress. Classification of neurotic disorders I.